000			03929nam a22003375i 4500
999			_c76646 _d76646 _x1
001			76646
003			ES-MaUEC
005			20230202102154.0
007			cr nn 008mamaa
008			140131s2013 ja | s |||| 0|eng d
020			_a9784431545569
024	7		_a10.1007/978-4-431-54556-9 _2doi
040			_dES-MaUEC
050		4	_aQR404.2.S45 _bN343 2013
100	1		_aNagai, Yoshiyuki. _eeditor literario _985851 _0Local
245	1	0	_aSendai Virus Vector : _bAdvantages and Applications _cedited by Yoshiyuki Nagai.
260			_aTokyo _bSpringer International Publishing _c2013
300			_a1 recurso en línea (XII, 210 p.) _b33 ilustraciones, 17 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_a1. Reverse genetics of Mononegavirales: the rabies virus paradigm Karl-Klaus Conzelmann -- Â{u0CAE} Sendai virus biology and engineering leading up to the development of a novel class of expression vector Yoshiyuki Nagai and Atsushi Kato -- Â{u0CEE} Concept and technology underlying Sendai virus (SeV) vector development Akihiro Iida and Makoto Inoue -- Â{u0D2E} Roadmap for development of a replication-deficient Sendai virus vaccine vector (provisional) Marian Wiegand and Wolfgang Neubert -- Â{u0D6E} Development of vaccines using SeV vectors against AIDS and other infectious diseases Sayuri Seki and Tetsuro Matano -- Â{u0DAE} BioKnife, a modified Sendai virus, to resect malignant tumors Yoshikazu Yonemitsu, Yasuji Ueda and Mamoru Hasegawa -- Â{u0DEE} Induction of human pluripotent stem cells by the Sendai virus vector:Establishment of a highly efficient and foot-print free system Noemi Fusaki and Hiroshi Ban -- ÂÎ Gene therapy for peripheral arterial disease using Sendai virus vector: From preclinical Studies to the phase I/IIa clinical trial Yoshikazu Yonemitsu, Takuya Matsumoto and Yoshihiko Maehara.
520			_aSendai virus (SeV) is not just a mouse pathogen but is evolving into a cutting-edge component of biotechnology. SeV reverse genetics originating from a pure academic need to settle long-held questions in the biology and pathogenicity of nonsegmented negative strand RNA viruses (Mononegavirales) is about to bear the impressive fruit of multipurpose cytoplasmic (non-integrating) RNA vectors. This book brings together in one source the SeV biology revealed by conventional approaches and reverse genetics, the methods to construct the first-generation SeV vector and to generate safer versions, and the applications in medical settings that have left or are about to leave the laboratory bench. The applications, which already are diverse and have high medical impact, include use as vaccine vectors against AIDS and respiratory virus infections, creation of BioKnife to resect malignant tumors, induction of “footprint (transgene) freeâ€{u0C2C}uripotent stem cells, and gene therapy for peripheral arterial disease. These achievementsâ€{u7A29}ch are just a few of many examplesâ€{u7972}e attainable only after rigorously incorporating the rich knowledge of SeV biology that has accumulated during the several decades since the discovery of the virus. Application of SeV vector is certain to expand greatly because of its extremely high performance in transgene expression and its remarkable target cell breadth.
650		7	_2embne _9413113 _aVirología
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-4-431-54556-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12822644 _b10-10-17 _c01-10-14
942			_2lcc _cLE
945			_aQR404.2.S45 N343 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11551859 _z06-04-17
988			_aEBSPRINGER
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _gja _h0